News

May 18, 2026

HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has received approval from […]
May 11, 2026

HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De […]
March 30, 2026

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the […]
October 22, 2025

HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 45.4 Million Elevance Health Members

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced that Elevance Health (formerly Anthem, […]
October 16, 2025

HistoSonics Announces Oversubscribed $250 Million Growth Financing

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed […]
August 8, 2025

Med-tech startup in Plymouth receives $2.25B investment

A nondescript industrial park in Plymouth is home to a med-tech startup that has been making some serious noise for […]
1 2 3 8

Last updated on May 18, 2026

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer last updated on June 30, 2025
X New Twitter Logo
© 2019-2026 HistoSonics®. All rights reserved.
HistoSonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.